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Loss of interleukin 33 expression in 
colonic crypts - a potential marker 
for disease remission in ulcerative 
colitis
Mona Dixon Gundersen1, Rasmus Goll1, Johanna Hol2, Trine Olsen1, Renathe Rismo1, 
Sveinung W. Sørbye1, Olav Sundnes2, Guttorm Haraldsen2 & Jon Florholmen1
Interleukin 33 (IL-33) is a cytokine preferentially elevated in acute ulcerative colitis (UC), inferring a 
role in its pathogenesis. The role of IL-33 in intestinal inflammation is incompletely understood, with 
both pro-inflammatory and regulatory properties described. There are also conflicting reports on 
cellular sources and subcellular location of IL-33 in the colonic mucosa, justifying a closer look at IL-33 
expression in well-defined clinical stages of UC. A total of 50 study participants (29 UC patients and 
21 healthy controls) were included from a prospective cohort of inflammatory bowel disease patients 
treated to disease remission with infliximab, a tumour necrosis factor alpha (TNF) inhibitor. To our 
knowledge this is the first study examining mucosal IL-33 expression before and after anti-TNF therapy. 
In colonic mucosal biopsies we found a 3-fold increase in IL-33 gene expression comparing acute UC to 
healthy controls (p < 0.01). A significant reduction of IL33 between acute UC and disease remission was 
observed when TNF normalised in the mucosa (p = 0.02). Immunostaining revealed IL-33 in the nuclei 
of epithelial cells of scattered colonic crypts in acute disease, while at disease remission, IL-33 was 
undetectable, a novel finding suggesting that enterocyte-derived IL-33 is induced and maintained by 
inflammatory mediators.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterised by a continuous, submucosal 
inflammation of the colon. The pathogenesis is complex and appears to involve both genetic susceptibility and 
environmental triggers, that together lead to an imbalance between pro- and anti-inflammatory cytokines in 
the intestinal mucosa and development of chronic inflammation1,2. This assumption is supported by the success 
of inhibiting the pro-inflammatory cytokine tumour necrosis factor alpha (TNF), which has proven effective in 
achieving mucosal healing in IBD3,4.
Interleukin 33 (IL-33), a member of the interleukin-1 family of cytokines, has generated interest in the 
research field of IBD following reports of its dysregulation5–9. Notably, IL-33 is predominantly elevated in acute 
IBD and most markedly in UC6–8,10–12. In addition, genetic polymorphisms of IL-33 or its receptor, IL1RL1 (alias 
IL-33R, ST2), are associated with an increased risk of IBD and a more extensive colitis9. In experimental colitis, 
IL-33 is found to induce both pro-inflammatory and tissue protective pathways6,13–18, the latter considering a 
crucial role for IL-33 in promoting tissue healing and raising the interest of IL-33 as a potential therapeutic target 
in IBD16,17.
IL-33 was initially discovered as a nuclear factor of high endothelial venules19. A wide range of cells have since 
been found to express IL-33, including cells at sites protecting the body from the outer environment such as the 
skin, airways and gastrointestinal tract13,20. The term “alarmin” is used to describe the role of IL-33 when released 
from injured or necrotic cells in response to tissue damage21,22. When released, IL-33 acts as a potent activator of 
the intestinal immune system by binding the transmembrane isoform of the IL-33 receptor IL1RL1. The IL-33/
IL1RL1 complex activates NF-κ B (nuclear factor kappa-light-chain-enhancer of activated B cells) and MAPK 
(mitogen-activated protein kinases), including induction of a TH2 cellular response in T cells5,22,23. Recent findings 
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also suggest that IL-33 promotes the differentiation of T regulatory cells in the intestine associated with protection 
against dysregulated inflammatory responses16. Murine models with DSS (dextran sulphate sodium) -induced 
colitis support the hypothesis of IL-33 as a dual function cytokine. Exogenous treatment with IL-33 has been 
shown by several independent groups to increase the severity of acute colitis6,13,15,24. Interestingly, mice deficient 
of IL-33 have a delayed recovery and resolution after an induced colitis episode18. In contrast to IL-33 therapy 
exacerbating DSS-colitis, a recent report found IL-33 treatment to promote epithelial repair driven by innate 
lymphoid type 2 cells and regenerative growth factors17. Taken together, this implies that the role of IL-33 in the 
pathogenesis of ulcerative colitis varies according to phases of inflammation and mucosal healing.
The aim of the current study was to characterize the modulation of IL-33 in the intestinal mucosa of patients 
with acute UC treated with infliximab, a TNF inhibitor, and to unravel the dynamics of IL-33 in the mucosal 
healing process. To our knowledge this is the first study that examines the mucosal response of IL-33 following 
anti-TNF therapy in IBD.
Results
Study population. Fifty study participants were included, 29 UC patients and 21 healthy controls. Baseline 
demographics for the study population are shown in Table 1.
Mucosal levels of IL33 mRNA are increased in acute UC. Quantitative PCR analysis revealed a 3-fold 
increase of mucosal IL33 transcripts in biopsies from acute UC lesions compared to healthy control sam-
ples (p < 0.001, Fig. 1a). Expression of the IL33 receptor IL1RL1 was also upregulated, as were several other 
pro-inflammatory cytokines shown in Fig. 1a. Data from individual patients are shown for IL33 and IL1RL1 
(Fig. 1c,d, respectively). We next assessed the modulation of this cytokine profile in each patient before and after 
infliximab therapy (acute disease versus remission), observing a strong reduction in several cytokines, whilst 
changes in transcript levels of IL33 or IL1RL1 did not reach statistical significance (Fig. 1b).
IL33 mucosal gene expression decreases when TNF levels normalise. The lack of reduction in IL33 
gene expression upon disease remission was somewhat surprising given the association of IL33 expression with a 
pro-inflammatory cytokine profile. We therefore stratified our cohort according to TNF-normalisation (defined 
as the upper limit of the 95% confidence interval of a previously published normal control group)25,26, resulting 
in two subgroups; those with normalised TNF mucosal levels (n = 10) and those with a raised mucosal TNF 
(n = 19). Cytokine expression was compared between these subgroups shown in Fig. 2a. A significant reduction of 
IL33 mRNA was only seen in the normalised TNF group (p = 0.02, see Fig. c), whereas we observed no difference 
with respect to IL1RL1 (Fig. 2a,c).
Loss of nuclear IL-33 in epithelial crypt cells in healed mucosa. Observing that IL33 transcription 
was only reduced in patients with normalised TNF levels, we next assessed the expression level of IL-33 protein 
by means of immunohistochemical analysis. Nine UC patients with mucosal biopsies taken from the same region 
at both acute inflammation (pre-infliximab) and at disease remission were included. In lesions of acute inflamma-
tion, 8 out of 9 biopsies showed a positive, nuclear IL-33 signal in epithelial cells in scattered colonic crypts. We 







Age study inclusion (years), mean ± SD 39.0 ± 12.7 56.1 ± 13.4
Disease duration, median months, [range] 58 [0–372]
Newly diagnosed <1month 2
Disease extent (n)
 - Proctitis 5
 - Left colitis 17
 - Pancolitis 7
Smoking status (n)
 - Never 15
 - Current 2
 - Ex smoker 11
 - Unknown 1
UCDAI pre, median,[range] 10 [7–12]
Endoscopic subscore, median, [range] 2 [2–3]
Medication (last 3 months) (n)
 - 5ASA 28
 - Steroids (oral) 20
 - Azathioprine or Methotrexate 11
Table 1.  Study population baseline demographics.
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did not detect any distinct pattern. Strikingly, IL-33 was undetectable in all colonic crypts and epithelial cells at 
the time point defined as disease remission following infliximab therapy (See Fig. 3). Interobserver agreement of 
quantification of IL-33 positive cells yielded a weighted kappa coefficient of 0.83 (data shown in Supplementary 
Table S1).
IL-33 in the lamina propria. IL-33 expression in the lamina propria of UC lesions was mainly found in 
vascular endothelial cells, and in myofibroblast-like cells7,11. Quantification of IL-33 positive cells in this com-
partment showed no change in the number of positive IL-33 cells in the lamina propria comparing acute UC 
with disease remission (Fig. 3c). In the normal control group (n = 10), only a few IL-33-positive lamina propria 
cells were observed, most of them morphologically assessed as vascular endothelial cells consistent with previous 
reports7,27. No IL-33 expressing cells were observed in the epithelial border or colonic crypts of the normal con-
trol group (Fig. 4).
Discussion
In this study we observed a selective induction of nuclear IL-33 in enterocytes in scattered crypts of acute UC 
lesions. Strikingly, this expression was lost following successful anti-TNF therapy to disease remission. These are 
novel findings providing insight into a dynamic expression of IL-33 in well-defined, clinical stages of UC.
Although IL-33 is consistently found to be elevated in acute UC, there is variation in the literature regarding 
its cellular location6–8,28,29, particularly in the epithelial intestinal barrier6–8,29. In this study we found that IL-33 
was present in nuclei of scattered epithelial crypt cells of patients with acute UC, while it was undetectable in dis-
ease remission and in healthy controls. These findings suggest that IL-33 may be an inflammation-induced factor 
in the human intestinal epithelial barrier. In support of this, recent studies at other epithelial barrier sites have 
described nuclear IL-33 to be associated with inflammation inferring a common pathway of IL-33 regulation, 
Figure 1. Expression of mucosal IL33 is increased in acute ulcerative colitis. Panel (a) shows an increase 
in mucosal mRNA expression for selected cytokines from colonic biopsies comparing acute ulcerative 
colitis (n = 29) with a healthy control group (n = 21). Panel (b) shows the same cytokine profile for patients 
with ulcerative colitis (n = 29) with a pairwise comparison of biopsies taken during active disease and at 
disease remission. No change was detected for IL33, IL1RL1 and IL4 (p > 0.05). Results for (a,b) are given 
as fold change (2−∆∆CT) with mean values, and the upper limit of the 95% confidence interval as error bars. 
Statistical analysis was performed using Mann U Whitney Test (a) and Wilcoxon Signed Ranks Test (b) with 
*p-value < 0.01, **p-value < 0.001 shown in panels. Panels (c) and (d) show individual values of relative gene 
expression (2−∆CT) of IL33 and IL1RL1, respectively, for acute disease and normal controls, with the horizontal 
line representing the median value.
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including squamous epithelium cells of the oesophagus, and keratinocytes of the skin epithelial barrier30,31. 
We hypothesised that the sporadic distribution of IL-33 positive intestinal crypts might be associated with 
areas of more severe inflammation such as crypt abscesses, proximity to epithelial injury or aggregates of 
Figure 2. Normalisation of TNF reduces mucosal IL33 gene expression. Pairwise comparison of colonic 
biopsies from patients with UC pre and post infliximab therapy (acute disease versus disease remission) were 
analysed with real-time qPCR. Patients are grouped into those who showed normalisation of mucosal TNF 
at disease remission (n = 10), and those who had a raised mucosal TNF at disease remission (n = 19). Results 
are given as mean fold change (2−∆∆CT) with error bars marking the upper limit 95% confidence interval. A 
more significant reduction of inflammatory cytokine transcription was seen in the group with normalisation of 
mucosal TNF, assessed by Wilcoxon Signed Ranks Test (a). Panels (b,c) show individual IL33 and IL1RL1 gene 
expression for each patient at acute disease (white point) and disease remission (black point) given as 2−∆CT, 
with ∆ CT values generated from the mean of the healthy control group. IL33 showed a significant reduction 
(p = 0.02) for the TNF normalised group but not when TNF remained elevated (p = 0.8).
Figure 3. IL-33 is present in epithelial crypts in acute ulcerative colitis. Panel (a) shows colonic biopsies 
from 3 representative patients with acute UC treated with infliximab (anti-TNF) to disease remission. 
Endoscopic biopsies were taken from the most inflamed colonic regions pre- infliximab therapy (acute disease), 
and repeated from the same region at disease remission. Biopsies were formalin fixed, paraffin embedded with 
immunoenzymatic staining for IL-33 (brown) using monoclonal mouse antibody (Nessy-1). IL-33 positive 
cells are seen in epithelial crypts during acute disease. At disease remission no epithelial staining for IL-33 was 
seen. Cell nuclei (blue) counterstained with hematoxylin. Scale bar = 0.1 mm. Panel (b) shows a representative 
whole biopsy from acute ulcerative colitis (x40 magnification) stained as above, whilst boxes show high-power 
magnification. Scale bar = 0.05 mm. Panel (c) shows quantification of IL-33 positive cells per mm2 in individual 
patients (n = 9) in the epithelium and lamina propria.
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inflammatory cells, however we did not observe any distinct pattern. Differences in biopsy orientation must be 
taken into account and may have underestimated our findings of IL-33 positive cells. Another hypothesis is that 
enterocyte-derived IL-33 is induced by local environmental factors in the individual lumen of colonic crypts, 
resulting in the scattered distribution observed.
IL-33 is described as a cytokine of dual functions, referring to its role as an endogenous alarmin, but also to its 
nuclear, transcriptional repressive functions21. We found IL-33 to be present in epithelial cells in association with 
inflammation, however our data do not imply whether IL-33 may act as an inducer or repressor of the inflamma-
tory response in this setting. Furthermore, the mechanisms regarding its downregulation, degradation or secre-
tion from the nuclei remain unknown. Future research should be designed to understand which inflammatory 
mediators induce and regulate IL-33 expression in crypt cells, and is an area of focus in our research group.
IL33 mucosal gene expression was increased in acute UC, alongside other known mediators of acute inflam-
mation including TNF. The normalisation of mucosal TNF-expression has previously been associated with 
long-term disease remission in UC32. Interestingly, we found a more pronounced downregulation of inflam-
matory cytokines in the subgroup of patients (n = 10) whom achieved normalisation of mucosal TNF levels, 
including a significant reduction of IL-33 (p = 0.02). In contrast, IL33 remained upregulated in the patient group 
Figure 4. Immunostaining of IL-33 in control groups. Panels (a,b) show formalin fixed, paraffin embedded 
biopsies with immunoenzymatic detection for IL-33 (brown) using monoclonal mouse antibody (Nessy-1) 
at [1 μ g/ml], with cell nuclei (blue) counterstained with hematoxylin. Panel (a) shows representative sections 
from colonic biopsies of 3 healthy controls. No IL-33 staining was observed in epithelial cells. IL-33 positive 
cells are seen in the stroma mainly associated with vascular endothelial cells (black arrow). Scale bar = 0.1 mm. 
Panel (b) shows from left to right; acute UC with a IL-33 positive colonic crypt, an isotype and concentration 
matched control from the same biopsy and a positive control using human tonsillar tissue. Scale bar = 0.1 mm. 
Immunofluorescence images (c) of formalin fixed, paraffin embedded colon biopsies from acute UC, with 
double staining performed for IL-33 polyclonal goat antibody (red) and IL-33 monoclonal mouse antibody 
(green). Merged image (left) shows good co-localisation of both antibodies (see white arrow), confirming 
antibody specificity. Cell nuclei are counterstained with Hoechst. Scale bar = 20 um.
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with raised TNF levels at clinical remission (see Fig. 2). These findings may indicate a time-lag for normalisation 
of IL33 in the intestinal mucosa, possibly dependent on a more complete normalisation of pro-inflammatory 
cytokines including mucosal TNF. The IL33 receptor IL1RL1 showed a similar tendency, however this must be 
interpreted with care as our assay did not differentiate between membranous and soluble isoforms of IL1RL1, an 
issue that should be addressed in future studies. From the above findings we propose that mucosal IL33 expres-
sion is only reduced at the stage of remission that allows for normalisation of mucosal TNF levels.
In this study, we have described a cohort of patients with a clinically similar disease course, all of whom 
were followed from acute UC to disease remission during anti-TNF treatment. Biological variation was reduced 
by comparing serial biopsies from the same patient. We were also able to examine the mucosal IL-33 response 
to modulation of TNF in vivo. In contrast to the significant reduction in epithelial IL-33 observed in response 
to anti-TNF treatment, we could not detect any reduction of IL-33 positive lamina propria cells (see Fig. 3). 
Several factors may be contributing to this result, including different cellular regulation of IL-33 expression. 
Endothelial cells, observed to be a main source of IL-33 positive cells in disease remission, show constitutive 
Notch-dependent IL-33 expression and this regulatory mechanism has not been described in other cell types33. 
Other factors include sample size (n = 9) and that endoscopic biopsies only sample the superficial layer of the 
colonic mucosa, excluding deeper stromal layers from our analyses.
Achieving disease remission is associated with a better prognosis in UC, and is the main goal of therapy34. 
Unresolved questions include when therapy can be successfully discontinued following achievement of disease 
remission. Based on previous findings we propose that clinical and endoscopic criteria are not sufficient for 
determining disease remission, and that evidence of mucosal normalisation of inflammatory mediators is also 
needed26,32.
Conclusion
We have characterized the expression of IL-33 in well-defined clinical stages of ulcerative colitis. IL-33 was pres-
ent in the nuclei of enterocytes in scattered colonic crypts in acute ulcerative colitis, but was not present in these 
cells at clinical disease remission. An overall reduction in IL-33 mucosal gene expression was only seen in patients 
with normalised mucosal TNF levels. Further studies to explore the regulation and nuclear role of IL-33 are war-
ranted, taking cellular location into account. The downregulation of epithelial IL-33 expression may potentially 
serve as a marker for disease remission in UC together with other biomarkers including mucosal TNF.
Materials and Methods
The study protocol, including storage of biological samples, was approved by the Regional Committee for Medical 
and Health Research Ethics North (Ref no: 1349/2012), and carried out in accordance with the Declaration of 
Helsinki Principles. Written and informed consent was obtained from all study participants.
Study population and inclusion criteria. Patients were recruited from a prospective study of IBD patients 
at the University Hospital of North Norway, aged ≥ 18 years. Mucosal biopsies were obtained from patients with 
moderate to severe UC defined by a Mayo score ≥ 6 at baseline35. Patients were diagnosed according to estab-
lished clinical, endoscopic and histological criteria36. All patients were treated with infliximab (anti-TNF therapy) 
intravenously 5 mg/kg at 0, 2 and 6 weeks, and every 4th week until disease remission, defined as a Mayo score ≤ 2 
with a endoscopic subscore of 0 or 1. Exclusion criteria included anti-TNF therapy within the last 12 weeks, 
pregnancy, previous cancer or primary sclerosing cholangitis. The control group consisted of patients referred to 
endoscopy at the outpatient clinic for bowel cancer screening. For this group, exclusion criteria were diarrhoea 
and presence of colonic polyps. All controls had a normal colonoscopy and a histological normal colonic mucosa 
assessed by two pathologists.
Colonic biopsies. Endoscopic mucosal biopsies were obtained from the most inflamed bowel region prior 
to start of infliximab therapy, and a new biopsy obtained from the same region at disease remission. Mucosal 
biopsies were taken from the rectum or sigmoid colon in healthy controls. A standard endoscopic biopsy forceps 
was used for mucosal biopsies which were immediately immersed in either 10% formalin or RNAlater (Ambion 
Inc., Austin, TX, USA). RNA was isolated using either the Promega method (Promega Corp., Madison, WI, USA) 
previously published in detail26,37, or with AllPrep RNA/DNA miniKit using Qiacube (Qiagen, Hilden, Germany), 
and stored at − 70 °C.
Quantitative PCR analysis. Reverse transcriptase was performed with Quantitect 2 step Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. Mucosal cytokines were measured in duplicates 
using hydrolysis probes. Beta actin (ACTB) was used as a reference gene for normalisation. The stability of ACTB 
in the current setting has previously been tested26. Positive and negative controls were included on each plate 
with standardised cycle thresholds. Assays, apart from interferon gamma (IFNG) were all in-house and listed 
in Supplementary Table S2. All data was expressed using ∆ CT values with fold change expressed as 2−∆∆CT. The 
laboratory investigators were blinded to the clinical data.
Immunostaining. Sections (4 μ m) of formalin-fixed, paraffin-embedded biopsies were deparaffinised and 
rehydrated. Antigen retrieval was performed in citrate buffer pH 6 in a water bath at 100 °C for 20 minutes, 
followed by 20 minutes cooling. IL-33 monoclonal mouse antibody (Nessy-1, Enzo life Sciences) was used at 
1 μ g/ml, or a polyclonal goat antibody for IL-33 at 0.1 μ g/ml (AF3625, R&D Systems). Primary antibodies were 
incubated for 60 minutes at room temperature or overnight at 4 °C. Enzymatic detection with 3,3 diaminoben-
zidine was performed with DAKO envision kit (DAKO, Glostrup, Denmark) following the manufacturer’s 
instructions and counterstained with hematoxylin. Negative controls were performed routinely with the pri-
mary antibody being substituted with an isotype- and concentration-matched antibody (mouse IgG1, DAKO). 
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Tonsillar tissue was used as positive control. For immunofluorescence detection slides were blocked with 10% 
donkey serum (20 minutes). Secondary antibodies conjugated with Alexa488 or Alexa546 (Life Technologies) 
were used, with Hoechst (33258, Life Technologies) as counterstain.
Images where obtained using Olympus BX51 microscope with an Olympus U-TVO.5XC camera using 
AnalySIS 3.2 software (Soft Imaging System). Immunofluorescence images were taken with a Zeiss Axio observer, 
Z1 LSM780 CLSM system (Carl Zeiss Microscopy GmbH, Jena, Germany) running the Zen 2012 (black edi-
tion) software. Images were processed in Adobe Photoshop CS6 (Adobe Systems Software Ireland Ltd, Dublin, 
Ireland), with adjustments to image histograms applied only for whole images. Two independent observers (SWS, 
MDG) performed quantification of IL-33 positive cells. 3 representative high field views of x 400 magnification 
per biopsy where counted for positive and negative epithelial and crypt cells and summarised in the following 
categories: negative < 1%, weak 1–9%, moderate 10–24%, high 25–49% and very high ≥ 50%. Positive cells in the 
stroma were counted per mm2 based on biopsy area calculations from NIS- elements AR 3.1 software (Nikon 
Instruments, Europe).
Statistical methods. All statistics are performed using IBM SPSS statistics version 22.0 (IBM corp., 
Armonk, NY, USA) or GraphPad Prism version 6.03 (La Jolla, CA, USA). Normality plots were assessed with 
histograms and Shapiro-Wilks test, with appropriate t-test or equivalent non parametric test used. Interobserver 
variability was assessed with weighted Cohen’s kappa for immunohistochemistry analysis.
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